Press release
Chronic Kidney Disease Market Size in the 7MM is Projected to Enhance at a Significant CAGR by 2036, Estimates DelveInsight
The market dynamics for Chronic Kidney Disease (CKD) is witnessing significant growth driven by the rising prevalence of diabetes, hypertension, obesity, and aging populations, which are major contributors to declining kidney function. Increasing awareness regarding early diagnosis, growing screening initiatives, and higher treatment uptake are further supporting market expansion. Additionally, the launch of emerging therapies such as atrasentan, zibotentan/dapagliflozin, and other novel renal-protective agents will further fuel the market.DelveInsight's "Chronic Kidney Disease Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover which therapies are expected to grab the Chronic Kidney Disease Market Share @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr
Key Takeaways from the Chronic Kidney Disease Market Report
• The market size for Chronic Kidney Disease in the leading markets is expected to grow significantly by 2036.
• The United States accounted for the highest Chronic Kidney Disease treatment market size in 7MM in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
• According to the findings, the 7MM accounted for a substantial diagnosed prevalent Chronic Kidney Disease patient pool in 2025, with cases expected to rise during the forecast period.
• In 2025, the US accounted for the highest number of Chronic Kidney Disease cases, followed by EU4 and the UK.
• The leading Chronic Kidney Disease Companies such as AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novartis, Chinook Therapeutics, and others.
• Promising Chronic Kidney Disease Pipeline Therapies such as atrasentan, zibotentan/dapagliflozin, BI 690517, and others.
Stay ahead in the Chronic Kidney Disease Therapeutics Market with DelveInsight's Strategic Report @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr
What is Chronic Kidney Disease?
Chronic Kidney Disease (CKD) is a long-term progressive condition in which the kidneys gradually lose their ability to filter waste products and excess fluids from the blood effectively. It commonly develops due to diabetes, hypertension, glomerulonephritis, and other metabolic or vascular disorders. CKD is classified into stages based on glomerular filtration rate (GFR) and kidney damage markers such as albuminuria. If left untreated, the disease can progress to kidney failure, requiring dialysis or kidney transplantation. Early diagnosis and treatment are essential to slow progression, reduce cardiovascular complications, and improve patient outcomes.
Chronic Kidney Disease Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases
• Stage-specific Cases of CKD
• CKD Cases by Cause
• CKD Cases by Age
• CKD Cases by Gender
• Advanced CKD Cases Eligible for Treatment
Download the report to understand which factors are driving Chronic Kidney Disease Epidemiology trends @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr
Chronic Kidney Disease Marketed Drugs
FARXIGA (dapagliflozin): AstraZeneca
FARXIGA is approved for Chronic Kidney Disease to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure.
JARDIANCE (empagliflozin): Boehringer Ingelheim/Eli Lilly
JARDIANCE is approved for use in patients with Chronic Kidney Disease to reduce kidney disease progression and cardiovascular risks in eligible patients.
KERENDIA (finerenone): Bayer
KERENDIA is a non-steroidal mineralocorticoid receptor antagonist approved for CKD associated with type 2 diabetes.
Chronic Kidney Disease Drugs and Companies
• Novartis: atrasentan
• AstraZeneca/Bayer: zibotentan/dapagliflozin
• Boehringer Ingelheim: BI 690517
To learn more about Chronic Kidney Disease treatment guidelines, visit @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr
Key Factors Driving Chronic Kidney Disease Market
• Rising prevalence of diabetes and hypertension: The primary driver of the CKD market is the growing burden of diabetes and hypertension, the two leading causes of kidney damage worldwide.
• Increasing aging population: Elderly populations are at higher risk of reduced kidney function, increasing the CKD patient pool globally.
• Growing awareness and early diagnosis: Expanded screening programs and awareness campaigns are improving detection rates and earlier intervention.
• Advancements in targeted renal therapies: The emergence of SGLT2 inhibitors, mineralocorticoid receptor antagonists, and endothelin receptor antagonists is expanding treatment options.
• Active clinical pipeline and regulatory support: Strong R&D pipelines and increasing focus on cardio-renal diseases are encouraging pharmaceutical companies to invest in CKD drug development.
Recent Developments in the Chronic Kidney Disease Market
• During 2025, AstraZeneca and Bayer continued advancement of the Phase III development program evaluating zibotentan/dapagliflozin in patients with CKD.
• In 2025, Novartis progressed clinical development activities for atrasentan in proteinuric kidney disease populations, supporting future market expansion opportunities.
Scope of the Chronic Kidney Disease Market Report
• Coverage- 7MM
• Study Period- 2022-2036
• Chronic Kidney Disease Companies: AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novartis, Chinook Therapeutics and others.
• Chronic Kidney Disease Pipeline Therapies: FARXIGA, JARDIANCE, KERENDIA, atrasentan, zibotentan/dapagliflozin, BI 690517 and others.
• Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease Market Drivers and Barriers
• Chronic Kidney Disease Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Chronic Kidney Disease Drugs in development @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr
Table of Contents
1. Chronic Kidney Disease Market Report Introduction
2. Executive Summary for Chronic Kidney Disease
3. SWOT Analysis of Chronic Kidney Disease
4. Chronic Kidney Disease Patient Share (%) Overview at a Glance
5. Chronic Kidney Disease Market Overview at a Glance
6. Chronic Kidney Disease Background and Overview
7. Chronic Kidney Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Kidney Disease
9. Chronic Kidney Disease Current Treatment and Medical Practices
10. Chronic Kidney Disease Unmet Needs
11. Chronic Kidney Disease Emerging Therapies
12. Chronic Kidney Disease Market Outlook
13. Country-Wise Chronic Kidney Disease Market Analysis (2022-2036)
14. Chronic Kidney Disease Market Access and Reimbursement of Therapies
15. Chronic Kidney Disease Market Drivers
16. Chronic Kidney Disease Market Barriers
17. Chronic Kidney Disease Appendix
18. Chronic Kidney Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Kidney Disease Market Size in the 7MM is Projected to Enhance at a Significant CAGR by 2036, Estimates DelveInsight here
News-ID: 4497820 • Views: …
More Releases from DelveInisight Business Research
Mulitple System Atrophy Pipeline Accelerates as 22+ Pharma Companies Rigorously …
DelveInsight's "Multiple System Atrophy Pipeline Insight 2026" report provides comprehensive insights about 22+ companies and 24+ pipeline drugs in the Multiple System Atrophy pipeline landscape. It covers the Multiple System Atrophy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple System Atrophy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
Breast Cancer Pipeline Accelerates as 250+ Pharma Companies Rigorously Develop D …
DelveInsight's "Breast Cancer Pipeline Insight 2026" report provides comprehensive insights about 250+ Breast Cancer companies and 300+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest…
Short Bowel Syndrome Therapeutics Market (7MM) is expected to grow from USD 2,50 …
DelveInsight's "Short Bowel Syndrome Treatment Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of Short Bowel Syndrome, historical and forecasted epidemiology as well as Short Bowel Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the Short Bowel Syndrome Treatment Market Report @ https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from Short Bowel Syndrome Market…
High-grade Glioma (HGG) Market is Projected to Grow Significantly by 2036 Owing …
The market dynamics for High-grade Glioma (HGG) are witnessing steady growth driven by the rising incidence of aggressive brain tumors, increasing demand for effective targeted therapies, and growing adoption of advanced immunotherapies and precision medicine approaches. Additionally, the launch of emerging therapies such as DB107-RRV (Denovo Biopharma), MDNA55 (Medicenna Therapeutics), EO2401 (Enterome), and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its latest…
More Releases for Chronic
Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030
This latest report researches the industry structure,…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share…
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, T …
Orbisreserach.Com Adds “H1 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Market Pipeline Review 2017 Trend Analysis Report Report” To Its Research Database
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape.
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…
